Morning Read: Affymetrix mulls new bid, SCOTUS hears ACA contraception case
Plus, Paul Allen puts $100 million into high-risk biotech research, more California hospitals hit by ransomware and Roger Daltrey pushes 21st Century Cures legislation.
Former Affymetrix execs make offer for company that competes with Thermo Fisher’s
The new company, called Origin Technologies, are making this play about a week before Affymetrix shareholders plan to vote on the Thermo Fisher deal. The new bid will offer shareholders $16.10 per share in cash, up from Thermo Fisher's offer of $14 per share, as the New York Times points out.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.